anti-MiHA donor T-lymphocytes (IRIC/HMR/Universite de Montreal/SpecificiT)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-MiHA donor T-lymphocytes (IRIC/HMR/Universite de Montreal/SpecificiT)
Drug Alias Nameanti-minor histocompatibility complex donor T-lymphocytes (IRIC/Hopital Maisonneuve-Rosemont/Universite de Montreal/SpecificiT)immunodominant minor histocompatibility antigens (Institute for Research in Immunology and Cancer)
ClassificationBiologics > AntigenCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstitute For Research In Immunology And Cancer
China Registration ClassN/A

Develop Information

Active CompaniesUniversite De MontrealIRICoRInstitute For Research In Immunology And Cancer +[5] 
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A